James Biehl - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Reporting relationship: Chief Legal Officer
Issuer ticker: N/A
Reported as of: 16 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2022, 18:00:35 UTC
Prior SEC filing: 26 Apr 2022
Next SEC filing: 02 Nov 2022
Source filing: View source filing
Reporting owner signature: By: /s/ Richard Cunningham as attorney-in-fact for James Biehl

Key filing fact

James Biehl filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.

Key facts

This page summarizes James Biehl's Form 4 filing for TYME TECHNOLOGIES, INC..
10 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 16 Sep 2022, 18:00.

Change

Previous filing in this sequence was filed on 26 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TYME transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -105,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Footnotes: F1

TYME transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -150
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: See Footnote
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -500,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $2.42
Footnotes: F4

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -253,200
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 253,200
Exercise price: $1.56
Footnotes: F5

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -360,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 360,000
Exercise price: $1.39
Footnotes: F6

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -500,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $1.43
Footnotes: F7

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -482,200
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 482,200
Exercise price: $0.3200
Footnotes: F8

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $2.95
Footnotes: F9

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -12,500
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $2.95
Footnotes: F10

TYME transaction Derivative

Employee Stock Option - Option to buy

Disposed to Issuer

Transaction value
Shares: -75,000
Change %: -100%
Price
Shares after: 0
Date: 16 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $2.90
Footnotes: F11

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James Biehl is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 11 footnotes

Footnote F1

Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,601 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.

Footnote F2

Disposed of pursuant to the merger agreement between the issuer and Syros in exchange for 6 shares of Syros common stock after giving effect to the Reverse Split, with cash paid in lieu of fractional shares.

Footnote F3

150 shares are owned by Mr. Biehl's spouse.

Footnote F4

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $55.23 per share, after giving effect to the Reverse Split.

Footnote F5

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,095 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.

Footnote F6

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 15,775 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.

Footnote F7

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.

Footnote F8

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,130 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.

Footnote F9

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 547 shares of Syros common stock for $67.32 per share, after giving effect to the Reverse Split.

Footnote F10

Footnote F11

This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,286 shares of Syros common stock for $66.18 per share, after giving effect to the Reverse Split.